23andMe Investor Day Presentation Deck

Today's News on 23andMe and GSK Collaboration • GSK has elected to extend the exclusive target discovery period of the collaboration for a fifth year • We will continue to discover and validate novel drug targets using 23andMe's proprietary genetic and health survey database o 23andMe will receive a one-time payment of $50 million • 23andMe elects for royalty option on collaboration program targeting CD96 o 23andMe will be eligible to earn tiered worldwide royalties up to the low double digits o The worldwide royalty option curtails 23and Me's future investment in this program and provides 23andMe with a potentially high value revenue stream if the program is successful Copyright © 2022 23andMe, Inc. 23andMe® 5

View entire presentation